S&P 500   4,401.69 (-0.19%)
DOW   34,509.92 (+0.42%)
QQQ   348.04 (-1.49%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.31 (-0.05%)
NIO   24.28 (-2.37%)
AMD   112.81 (-3.19%)
CGC   7.48 (+1.08%)
MU   81.69 (-1.52%)
GE   91.78 (-5.29%)
T   26.41 (+0.27%)
F   20.15 (-1.18%)
DIS   136.93 (-0.39%)
AMC   16.39 (-1.50%)
PFE   52.65 (+2.15%)
ACB   4.25 (-1.62%)
BA   203.88 (-0.16%)
S&P 500   4,401.69 (-0.19%)
DOW   34,509.92 (+0.42%)
QQQ   348.04 (-1.49%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.31 (-0.05%)
NIO   24.28 (-2.37%)
AMD   112.81 (-3.19%)
CGC   7.48 (+1.08%)
MU   81.69 (-1.52%)
GE   91.78 (-5.29%)
T   26.41 (+0.27%)
F   20.15 (-1.18%)
DIS   136.93 (-0.39%)
AMC   16.39 (-1.50%)
PFE   52.65 (+2.15%)
ACB   4.25 (-1.62%)
BA   203.88 (-0.16%)
S&P 500   4,401.69 (-0.19%)
DOW   34,509.92 (+0.42%)
QQQ   348.04 (-1.49%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.31 (-0.05%)
NIO   24.28 (-2.37%)
AMD   112.81 (-3.19%)
CGC   7.48 (+1.08%)
MU   81.69 (-1.52%)
GE   91.78 (-5.29%)
T   26.41 (+0.27%)
F   20.15 (-1.18%)
DIS   136.93 (-0.39%)
AMC   16.39 (-1.50%)
PFE   52.65 (+2.15%)
ACB   4.25 (-1.62%)
BA   203.88 (-0.16%)
S&P 500   4,401.69 (-0.19%)
DOW   34,509.92 (+0.42%)
QQQ   348.04 (-1.49%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.31 (-0.05%)
NIO   24.28 (-2.37%)
AMD   112.81 (-3.19%)
CGC   7.48 (+1.08%)
MU   81.69 (-1.52%)
GE   91.78 (-5.29%)
T   26.41 (+0.27%)
F   20.15 (-1.18%)
DIS   136.93 (-0.39%)
AMC   16.39 (-1.50%)
PFE   52.65 (+2.15%)
ACB   4.25 (-1.62%)
BA   203.88 (-0.16%)
NYSE:GSK

GlaxoSmithKline Dividend Yield, History & Payout Ratio

$44.39
+0.01 (+0.02%)
(As of 01/25/2022 02:40 PM ET)
Add
Compare
Today's Range
$43.73
$44.39
50-Day Range
$41.02
$46.82
52-Week Range
$33.53
$46.85
Volume
293,524 shs
Average Volume
4.71 million shs
Market Capitalization
$119.52 billion
P/E Ratio
18.81
Dividend Yield
4.52%
Beta
0.75

Dividend Summary

Dividend Yield
4.60%

Annual Dividend
$2.04

3-Year
Dividend Growth
2.94%

Dividend Payout Ratio
86.44%

Recent
Dividend Payment
Jan. 13

Skip Charts & View Dividend History

Dividend Payments by Month (or Quarter)

Dividend Yield Over Time


GlaxoSmithKline (NYSE:GSK) vs. Its Competitors

TypeGlaxoSmithKlineMedical CompaniesNYSE Companies
Annual Dividend$2.04$1.43$1.44
Dividend Yield4.60%2.06%3.58%
3 Year Dividend Growth2.94%19.18%46.14%

GlaxoSmithKline (NYSE:GSK) Payout Ratio Breakdown

TypePayout Ratio
Based on Trailing 12 Months of Earnings86.44%
Based on This Year's Estimates67.77%
Based on Next Year's Estimates63.16%
Based on Cashflow55.56%

GlaxoSmithKline (NYSE:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2021quarterly$0.52344.7%11/18/202111/19/20211/13/2022
7/30/2021Quarterly$0.52305.2%8/19/20218/20/202110/7/2021
5/5/2021quarterly$0.63675.3%5/20/20215/21/20217/8/2021
2/4/2021quarterly$0.62805.7%2/18/20212/19/20214/8/2021
10/29/2020quarterly$0.49595.9%11/12/202011/13/20201/14/2021
7/30/2020quarterly$0.49144.9%8/13/20208/14/202010/8/2020
4/30/2020quarterly$0.47204.7%5/14/20205/15/20207/9/2020
2/6/2020quarterly$0.59944.6%2/20/20202/21/20204/9/2020
5/3/2019quarterly$0.49534.86%5/16/20195/17/20197/11/2019
2/8/2019quarterly$0.59705.81%2/21/20192/22/20194/11/2019
11/1/2018quarterly$0.48604.9%11/15/201811/16/20181/10/2019
7/25/2018Quarterly$0.49604.77%8/9/20188/10/201810/11/2018
4/26/2018quarterly$0.52985.27%5/10/20185/11/20187/12/2018
2/7/2018Quarterly$0.63306.48%2/22/20182/23/20184/12/2018
10/26/2017quarterly$0.50375.51%11/9/201711/10/20171/11/2018
7/26/2017Quarterly$0.49104.88%8/9/20178/11/201710/12/2017
4/26/2017quarterly$0.48304.79%5/10/20175/12/20177/13/2017
2/8/2017quarterly$0.57105.76%2/22/20172/24/20174/13/2017
10/26/2016$0.459011/2/201611/4/20161/12/2017
7/27/2016$0.49408/10/20168/12/201610/13/2016
4/28/2016$0.54905/11/20165/13/20167/14/2016
10/28/2015$0.577011/10/201511/13/20151/14/2016
5/7/2015quarterly$0.57695.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.69526.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.61305.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.64825.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.74965.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.61614.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.55324.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.55024.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.06900.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)













GlaxoSmithKline (NYSE:GSK) Dividend Frequently Asked Questions

What is GlaxoSmithKline's dividend yield?

The current dividend yield for GlaxoSmithKline (NYSE:GSK) is 4.60%. Learn more on GSK's dividend yield history

How much is GlaxoSmithKline's annual dividend?

The annual dividend for GlaxoSmithKline (NYSE:GSK) is $2.04. Learn more on GSK's dividend details

How often does GlaxoSmithKline pay dividends?

GlaxoSmithKline (NYSE:GSK) pays quarterly dividends to shareholders.

When was GlaxoSmithKline's most recent dividend payment?

GlaxoSmithKline's most recent quarterly dividend payment of $0.5234 per share was made to shareholders on Thursday, January 13, 2022.

Is GlaxoSmithKline's dividend growing?

Over the past three years, GlaxoSmithKline's dividend has grown by 2.94%.

When did GlaxoSmithKline last increase or decrease its dividend?

The most recent change in GlaxoSmithKline's dividend was an increase of $0.0004 on Friday, October 29, 2021.

What is GlaxoSmithKline's dividend payout ratio?

The dividend payout ratio for GSK is:
  • 86.44% based on the trailing year of earnings
  • 67.77% based on this year's estimates
  • 63.16% based on next year's estimates
  • 55.56% based on cash flow
This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.